Rheumatology Advance Access originally published online on February 3, 2006
Rheumatology 2006 45(8):982-989; doi:10.1093/rheumatology/kel030
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Tumour necrosis factor 
inhibitors in the treatment of childhood uveitis
Division of Rheumatology, 1 Department of Ophthalmology and Vision Sciences, 2 Departments of Paediatrics and Medicine, Hospital for Sick Children, Toronto, Canada and 3 North Toronto Eye specialists, Toronto, Canada.
Correspondence to: R. Saurenmann, Zurich University Children's Hospital, Postal Box 8032, Zürich, Switzerland. E-mail: traudel.saurenmann{at}kispi.unizh.ch
Objective. To describe the efficacy of anti-TNF-
agents in the treatment of childhood uveitis.
Methods. We performed a retrospective chart review of all children with uveitis treated with TNF- blockers at The Hospital for Sick Children, Toronto.
Results. Twenty-one children with uveitis were treated with the anti-TNF- agents etanercept (11 patients) and infliximab (13 patients), resulting in 24 treatment courses. All patients had persistently active uveitis despite treatment with at least one standard immunosuppressive drug before the start of anti-TNF- therapy. Six of 21 patients (29%) had idiopathic uveitis. In the other 15 patients, the underlying disease was juvenile idiopathic arthritis in 12 (57%), Behçet disease in two (9%) and sarcoidosis in one (5%). Response to etanercept treatment was good in 27%, moderate in 27% and poor in 45% of patients. Response to infliximab treatment was good in 38%, moderate in 54% and poor in 8% of patients. The difference in the percentage of patients with a moderate or good response was statistically significant (P=0.0481). We also observed a lower rate of complications, such as new-onset or worsening glaucoma or cataract in the infliximab-treated group.
Conclusion. Anti-TNF- treatment was beneficial in a high percentage of patients with childhood uveitis refractory to standard immunosuppressive treatment. Infliximab resulted in better clinical responses with less ocular complications than etanercept.
KEY WORDS: Biological agents, Eye diseases, Juvenile idiopathic arthritis, Outcome assessment
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. Simonini, M. E. Zannin, R. Caputo, F. Falcini, M. de Martino, F. Zulian, and R. Cimaz Loss of efficacy during long-term infliximab therapy for sight-threatening childhood uveitis Rheumatology, October 1, 2008; 47(10): 1510 - 1514. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Cobo-Ibanez, M. del Carmen Ordonez, S. Munoz-Fernandez, R. Madero-Prado, and E. Martin-Mola Do TNF-blockers reduce or induce uveitis? Rheumatology, May 1, 2008; 47(5): 731 - 732. [Full Text] [PDF]
|
|
|
|
|
|
P. Tynjala, K. Kotaniemi, P. Lindahl, K. Latva, K. Aalto, V. Honkanen, and P. Lahdenne Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis Rheumatology, March 1, 2008; 47(3): 339 - 344. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Guillaume-Czitrom, C. Berger, C. Pajot, B. Bodaghi, B. Wechsler, and I. Kone-Paut Efficacy and safety of interferon-{alpha} in the treatment of corticodependent uveitis of paediatric Behcet's disease Rheumatology, October 1, 2007; 46(10): 1570 - 1573. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Li Which Children with Juvenile Idiopathic Arthritis Are at Risk for Blindness? AAP Grand Rounds, June 1, 2007; 17(6): 65 - 65. [Full Text] [PDF]
|
|
|
|
|
|
P. P. Sfikakis, N. Markomichelakis, E. Alpsoy, S. Assaad-Khalil, B. Bodaghi, A. Gul, S. Ohno, N. Pipitone, M. Schirmer, M. Stanford, et al. Anti-TNF therapy in the management of Behcet's disease--review and basis for recommendations Rheumatology, May 1, 2007; 46(5): 736 - 741. [Full Text] [PDF]
|
|
|
|
 |
|
 A. M Mansour Adalimumab in the therapy of uveitis in childhood Br. J. Ophthalmol., March 1, 2007; 91(3): 274 - 276. [Full Text] [PDF]
|
|